This page shows the latest influenza news and features for those working in and with pharma, biotech and healthcare.
Xofluza offers patients the first novel mechanism of action for treating influenza approved in Europe in almost 20 years. ... found that the drug had a statistically significant prophylactic effect on influenza occurrences.
Xofluza was first approved by the FDA last year, and is available as a treatment for acute, uncomplicated influenza in people aged 12 years and older. ... We’re hopeful that reducing the burden of influenza may help to mitigate the strain on our
Sanofi’s Supemtek is the now first and only recombinant influenza vaccine to be approved within the European Union. ... countries. “In the context of the COVID-19 pandemic, preventing influenza remains a public health priority,” said Thomas Triomphe
A number of studies have shown that a decreasing immune function caused by ageing results in a decreased immune response to vaccines, with this response previously observed for vaccines for influenza
It is also approved in the US for the treatment of people who have a high risk of developing influenza-related complications. ... found that the drug had a statistically significant prophylactic effect on influenza occurrences.
This might carry additional advantages of treating COVID19 when it occurs alongside infection by another respiratory virus such as influenza or Respiratory Syncytial Virus that may well be encountered in the
More from news
Approximately 19 fully matching, plus 205 partially matching documents found.
worldwide, Dr Schaffner had a point to call attention to the dangers of influenza. ... As such, policymakers are continuing to stress the importance of planning for seasonal influenza circulation this winter.
By Chris Finch. Pre-COVID-19, the H1N1 influenza pandemic of 1918 was the most severe global pandemic in modern history.
In John M Barry’s 2009 Nature essay titled Pandemics: Avoiding the Mistakes of 1918, he said: ‘In the next influenza pandemic.
What are the shortcomings of current influenza vaccines, and why are new products needed? ... The outcome measurement is to decrease the amount of laboratory-confirmed influenza illness.
76% of delegates felt more confident in their ability to manage the influenza vaccination. ... influenza infection, particularly among the more at-risk group of 65 years and over.
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness.
patients suffering from serious infections such as influenza to get better, faster.
Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.
systems teams as well as a specialist influenza vaccines unit.
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
influenza vaccine.
Epidemics of measles are occurring across Europe. Rates of vaccination for influenza, HPV, tetanus and polio have also declined.
The way that influenza spreads can be tracked by tools such as Flusurvey,(1) which produces rapidly-updated heatmaps of illness across the country.
Agency: BASTARD. LONDON. Product: Self Promotion. Client: Self Promotion. Therapy area: Self Promotion. View the PMHub profile for: BASTARD. LONDON.
More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...